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Health Impacts and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, USA
Quantitative exposure data is important for evaluating toxicity risk and biomonitoring
is a critical tool for evaluating human exposure. Direct personal monitoring provides
the most accurate estimation of a subject’s true dose, and non-invasive methods
are advocated for quantifying exposure to xenobiotics. In this regard, there is a
need to identify chemicals that are cleared in saliva at concentrations that can be
quantified to support the implementation of this approach. This manuscript reviews
the computational modeling approaches that are coupled to in vivo and in vitro
experiments to predict salivary uptake and clearance of xenobiotics and provides
additional insight on species-dependent differences in partitioning that are of key
importance for extrapolation. The primary mechanism by which xenobiotics leave the
blood and enter saliva involves paracellular transport, passive transcellular diffusion,
or transcellular active transport with the majority of xenobiotics transferred by passive
diffusion. The transcellular or paracellular diffusion of unbound chemicals in plasma
to saliva has been computationally modeled using compartmental and physiologically
based approaches. Of key importance for determining the plasma:saliva partitioning
was the utilization of the Schmitt algorithm that calculates partitioning based upon the
tissue composition, pH, chemical pKa, and plasma protein-binding. Sensitivity analysis
identified that both protein-binding and pKa (for weak acids and bases) have significant
impact on determining partitioning and species dependent differences based upon
physiological variance. Future strategies are focused on an in vitro salivary acinar cell
based system to experimentally determine and computationally predict salivary gland
uptake and clearance for xenobiotics. It is envisioned that a combination of salivary
biomonitoring and computational modeling will enable the non-invasive measurement
of chemical exposures in human populations.
Keywords: saliva, biomonitoring, salivary gland, uptake, clearance, pesticides
Introduction
The National Research Council of the National Academies report, Toxicity Testing in the 21st
Century: A Vision and Strategy, highlighted the importance of quantitative exposure data for
evaluating human toxicity risk (Hubal, 2009). The report supports the use of chemical exposure
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data to provide critical information on the magnitude, timing,
and duration of a biologically relevant dose delivered to target
tissues (Sheldon and Cohen Hubal, 2009; Cohen Hubal et al.,
2010). Direct measurement of chemical exposures using personal
monitoring provides the most accurate estimation of a subject’s
true exposure (Nieuwenhuijsen et al., 2006). In this context,
biomonitoring is a critical tool for quantitatively evaluating
exposure from both environmental and occupational settings
to a wide range of pollutants, including pesticides (Borzelleca
and Skalsky, 1980; Nigg and Wade, 1992; Friberg and Elinder,
1993; Christensen, 1995; Angerer et al., 2006, 2007; Barr et al.,
2006). Non-invasive methods have also been advocated for
quantifying the pharmacokinetics and bioavailability of drugs
and xenobiotics, and the use of saliva has been suggested
as an ideal body ﬂuid that can be substituted for blood in
biomonitoring (Pichini et al., 1996; Timchalk et al., 2004;
Timchalk et al., 2007b). In this regard, a broad range of drugs,
organic chemicals, metals, and pesticides are readily secreted
in saliva (Borzelleca and Skalsky, 1980; Drobitch and Svensson,
1992; Nigg and Wade, 1992; Lu et al., 1997, 1998; Silva et al.,
2005). Formany of these xenobiotics, saliva concentration readily
correlates with blood concentration; hence, it is feasible to utilize
pharmacokinetic models to accurately estimate systemic dose
based upon a saliva measurement.
The mechanism of acinar cell activation, electrolyte transport
and saliva formation illustrated in Figure 1 is derived from
an extensive literature that has characterized these processes
in detail (Nauntofte, 1992). Salivary glands are comprised of
a number of major (parotid, submandibular, and sublingual)
and minor glands that primarily consist of acinar cells that
collectively produce saliva (for review, see Hold et al., 1995b).
Salivary glands are highly perfused and blood ﬂow is in a
countercurrent direction to salivary ﬂow (Figure 1B; Davenport,
1977). The primary mechanism by which xenobiotics leave
the blood and enter saliva is thought to involve paracellular
transport, passive transcellular diﬀusion, or transcellular active
transport (Figure 1A; Landon and Mahmod, 1982). Paracellular
transport (i.e., ultraﬁltration) favors small (MW ∼300 Da)
polar lipid insoluble molecules that generally have a low (i.e.,
<1.0) saliva/plasma (S/P) ratio. Whereas, transcellular diﬀusion
or active transport are favored by lipid soluble materials that
can readily cross cell membranes (Hold et al., 1995a). The
majority of drugs and xenobiotics are cleared from plasma
into saliva by a passive diﬀusion process that is a function
of concentration gradient, surface area, membrane thickness,
and diﬀusion constants (Hold et al., 1995b). This focused
review will describe how the modeling of this passive diﬀusion
process in both rats and humans was accomplished utilizing
a pharmacokinetic model that were initially developed for
the organophosphorus insecticide chlorpyrifos (CPF) and its
major metabolite trichloropyridinol (TCPy; Smith et al., 2010,
2012).
It is well recognized that biomonitoring oﬀers one of the best
strategies for quantifying human dosimetry and assessing risk
associated with both occupational and environmental chemical
exposures (Friberg and Elinder, 1993; Christensen, 1995). As
noted above, saliva has been suggested as an ideal non-invasive
body ﬂuid, yet there are a number of limitations which have
hampered saliva’s use in biomonitoring. First, to utilize saliva
for biomonitoring the relationship between blood and saliva
FIGURE 1 | Schematic model illustrating (A) acinar cell and (B) salivary duct function associated with saliva formation. PEST is used as a general
notation for pesticides.
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concentrations for target biomonitoring, analytes needs to be
well established (Timchalk et al., 2004). Second, to more broadly
exploit saliva as a matrix it is critical to a priori identify
which chemicals are readily cleared in saliva at levels that can
be quantiﬁed analytically. The current manuscript reviews the
initial saliva model development focused on in vivo uptake
and clearance studies in the rat as well as computational
prediction in humans (Smith et al., 2010, 2012). In addition,
a partitioning coeﬃcient algorithm that readily accommodates
species-dependent diﬀerences in plasma protein-binding and
pH is presented. This is of particular importance since changes
in binding and/or pH appear to have a signiﬁcant impact on
plasma:saliva partitioning thereby contributing to variable saliva
analyte concentrations. Finally, a brief perspective on the utility
of cell based in vitro assay systems and computational modeling
are presented as a potential strategy for broad based screening
of chemicals for their salivary clearance potential (Weber et al.,
2015).
Computational Methods
Pharmacokinetic Modeling Strategy
The overarching computational modeling approach utilizes
a physiologically based pharmacokinetic (PBPK) model as
illustrated in Figure 2. Within this PBPK model both the
CPF and TCPy blood to saliva pharmacokinetics in the rat
was handled as a simple one-compartment pharmacokinetic
model as previously described (Smith et al., 2012). The model
was further modiﬁed to enable the prediction of CPF and
TCPy concentrations in human saliva after simulated exposures,
by accommodating diﬀerential partitioning based upon species
dependent diﬀerences in pH (see below for details). In this model,
CPF and it neurotoxic metabolite chlorpyrifos-oxon (CPF-
oxon) were distributed among internal compartments mediated
by blood circulation described as a ﬂow-limited process. The
FIGURE 2 | Schematic model illustrating physiologically based
pharmacokinetic (PBPK) model structure for simulating in vivo salivary
gland clearance of pesticides.
fraction of CPF or TCPy that was not bound to plasma-protein
is described simply as a fraction bound, where FBCPF or FBTCPy
are the fractions of CPF or TCPy bound to plasma-proteins,
CCPFb and CTCPyb are the concentration of CPF or TCPy
bound to plasma proteins, and CCPFbl and CTCPybl are the total
concentration of CPF or TCPy in blood, respectively (Eqs 1
and 2). The free CPF and TCPy concentrations (i.e., CCPF f and
CTCPy f) are available to partition to various tissue compartments
based upon their tissue speciﬁc partition coeﬃcients (Timchalk
et al., 2002). Fractional plasma protein-binding of CPF and
TCPy were measured previously and both determined to be
∼98–99% bound (Lowe et al., 2009; Smith et al., 2010). As CPF-
oxon undergoes rapid hydrolysis in the presence of albumin, it
was assumed that CPF and CPF-oxon have equivalent fraction
binding in plasma. Human metabolic parameters, including CPF
dearylation, CPF desulfuration, and CPF-oxon hydrolysis, were
updated (Smith et al., 2011). Other human parameters were
also updated from a variety of literature sources, including
cholinesterase activities, enzyme aging, degradation, reactivation,
and turnover rates (Sidell and Kaminskis, 1975; Hojring and
Svensmark, 1976; Maxwell et al., 1987; Mortensen et al., 1998;
Li et al., 2005; Albers et al., 2010; Smith et al., 2011). To
accommodate the eﬀects of isoﬂurane anesthesia (required
during in vivo experiments) on rat physiology, the cardiac output
was reduced 15% from standard values based upon observed
in vivo eﬀects [15 × body weight (kg)0.75; Conzen et al., 1992;
Vollmar et al., 1992; Brown et al., 1997].
CPF : CCPF f = CCPFbl × FBCPF (1)
TCPy : CTCPy f = CTCPybl × FBTCPy (2)
Saliva Partitioning
In the current PBPK model structure, transport of CPF or
TCPy from blood to saliva is modeled as a passive diﬀusion
process based upon their respective partitioning. Brieﬂy, for both
analytes the saliva concentration (Csal) was deﬁned as their blood
concentration (Cbl) multiplied by the saliva/blood partitioning
coeﬃcient (Psal/bl) [Eq. 3], which was determined experimentally
(in rats) using the mean saliva/blood concentration ratio.
Csal = Cbl × Psal/bl (3)
However, due to experimentally observed saliva pH changes
in rats (8.5–9.5; Smith et al., 2010), and the reported variability
in saliva pH between humans (6.2–7.4), species diﬀerences
may exist for ionizable compounds with pKa/pKb values near
physiologically relevant pH ranges. Thus in the absence of
human-speciﬁc experimental data, algorithms can be useful
for estimating partitioning and/or extrapolating partitioning
measured in animal models. Numerous partitioning algorithms
exist (Poulin and Krishnan, 1995; Rodgers et al., 2005; Schmitt,
2008; Peyret et al., 2010). Here, the Schmitt algorithm was
utilized, because it is the only algorithm that has been previously
validated for predicting salivary partitioning measured in rats
(Schmitt, 2008; Smith et al., 2010). The approach calculates
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partition coeﬃcients based upon the tissue composition in
terms of water, lipid and phospholipid contents, proteins, pH
diﬀerences using chemical compound-speciﬁc lipophilicity, pKa,
as well as plasma protein-binding. As noted in Smith et al. (2010),
this algorithm assumes that ionized compounds are capable
of traversing membranes, although at a much lower rate (∼3-
orders of magnitude) than non-ionized forms and estimates
the diﬀerence in rates based upon the ratio of distribution
coeﬃcients for the ionized and unionized forms (Schmitt,
2008).
The Schmitt algorithm was adapted for use in saliva (Schmitt,
2008; Smith et al., 2010). This original approach did not consider
salivary partitioning, thus “tissue-speciﬁc” parameters were used
to make these predictions with saliva (Table 1). Otherwise the
Schmitt algorithm was used as described (Schmitt, 2008). Brieﬂy,
for each of the model compartments, the unbound fraction
(fu; Eq. 4) is the ratio of analyte unbound concentration (Cu)
over total concentration (Ctotal). Generally, it is thought that
neutral compounds cross biological membranes much more
easily than charged compounds. Thus pH gradients that exist
across membranes can have a profound inﬂuence on the ability
of ionizable compounds to cross that barrier, where the ratio
of ionized to neutral compounds can vary by pH and the pKa
of the compound. For example, a week acid can accumulate
of the side of the barrier that has the higher pH, since the
ionized form cannot cross the membrane as easily as the
uncharged compound. The equilibrium salivary gland:blood
(Psal:bl) partitioning coeﬃcient is based upon the relationships
expressed in Eq. 5; where Ct , Cp, Cint , and Ccell are the total
concentrations in saliva tissue, plasma, interstitial, and cellular
spaces, respectively. The volume fractions of interstitial and
TABLE 1 | Input parameters for a modified algorithm for calculating the
saliva:blood trichloropyridinol (TCPy) partitioning coefficient (based upon
Schmitt, 2008).
Parameter Value (rat/human) Source (rat/human)
TCPy physiochemical properties
Fraction unbound in plasma 0.015 Measured/estimated
pKa 4.55 Fixeda
Log Kow at 7 pH 1.3 Fixeda
Log Kow at 3 pH 3.2 Fixeda
α 0.013 Calculatedb
Tissue properties
Plasma
Fraction protein 0.073 Fixedc
Fraction water 0.915 Fixedc
pH 7.8/7.4 Measured/fixed
Saliva
Fraction cells 0 Estimatedd
Fraction protein 0.003 Fixedc
Fraction water 0.98 Fixedc
pH 8.9/6.7 Measured/fixedc
aRacke (1993) and Shemer et al. (2005)
bα ratio of Kow at pH 7 and 3 (Schmitt, 2008)
cRitschel and Tompson (1983) and Hold et al. (1995b)
dAssume cellular fraction of saliva negligible.
cellular space are Fint and Fcell while the unbound fractions in
interstitial, cellular and plasma are f intu , f cellu , and f
p
u , respectively.
The unbound fraction in the interstitial space is estimated relative
to the unbound fraction in plasma, based on the fact that
the interstitial ﬂuid is quite similar to plasma but with lower
concentrations of proteins and lipids (Schmitt, 2008); whereas the
unbound fraction in the cellular space is determined by chemical
aﬃnity for cellular macromolecules such as protein and lipids
(both neutral and charged phospholipids). Finally, the tissue
pH gradients are critical since they will inﬂuence the unbound
concentrations for weak acids and bases which are charged
under physiological conditions. This is of particular importance
when considering salivary gland clearance where saliva formation
results in acinar cell acidiﬁcation (see Figure 1) as a result of
carbonic anhydrase conversion of CO2 and H2O to HCO3− and
H+ (Nauntofte, 1992).
fu = CuCtotal (4)
Psal:bl = CtCp =
Ct
Cu
Cu
Cp
= FintCint + Fcell Ccell
Cu
Cu
Cp
=
(
Fint
f intu
+ Fcell
f cellu
)
f pu
(5)
Parameter inputs (Table 1) for this algorithm include:
physical/chemical properties of CPF and TCPy, physiological
properties of rat and human plasma and mixed saliva;
additional assumptions included pH dependent partitioning to
the interstitial space fraction and negligible cellular fraction of
saliva (Ritschel and Tompson, 1983; Racke, 1993; Hold et al.,
1995b; Shemer et al., 2005).
Salivary Flow Rate
To experimentally obtain adequate saliva from rats, animals
were administered a cholinergic agonist, pilocarpine to induce
signiﬁcant salivation (Timchalk et al., 2006; Smith et al., 2010). To
facilitate a more accurate model simulation of this physiological
response, the salivary ﬂow rate (Qsal) was deﬁned as a non-linear
dynamic equation where A, B, and C are constants used to ﬁt
salivary ﬂow rate data (Smith et al., 2010) from rats infused
(3 ml/h) with pilocarpine (1 mg/ml; Eq. 6).
Qsal(t) = A × tB + C (6)
The CPF or TCPy elimination rates in saliva were deﬁned as
their respective concentrations in saliva (Csal) multiplied by the
saliva ﬂow rate (Eq. 7). However, PBPK model simulations of
humans did not accommodate diﬀerences in saliva ﬂow rates.
dCsal
dt
= −Csal × Qsal (7)
Sensitivity Analysis
To provide additional insight into the relative importance of
model parameters, as part of this review, a local sensitivity
analysis was conducted to identify the most important
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parameters for estimating the plasma:saliva partitioning
coeﬃcient for a generic compound with 50% plasma-protein
binding, pKa = 7.0, log Kow (non-ionized) = 2 and log Kow
(ionized) = −1. The analysis focused on the impact of changes in
these parameters on the partitioning coeﬃcient at steady-state.
The normalized sensitivity coeﬃcients were calculated for a 1%
change in a given model parameter when all other parameters
were held ﬁxed. Sensitivity analysis was performed using the
forward diﬀerence method coded in acslX version 3.0.2.1 (AEgis
Technologies, Inc., Huntsville, AL, USA).
Saliva Model Development Review
Initial in vivo studies in rats focused on the comparison of
blood and saliva TCPy concentration time-course following
intravenous (IV) administration of the CPF over a broad dose
range (0.5–5 mg/kg). These in vivo experiments focused on
exposing rats to CPF by IV administration and quantifying
the time-course of CPF and TCPy in both blood and saliva
over a range of CPF doses. Previous studies have characterized
route-dependent pharmacokinetic diﬀerences in rats, and IV
administration was chosen for these studies tominimize ﬁrst-pass
hepatic metabolism thereby maximizing the concentration of
CPF in blood available for salivary clearance (Busby-Hjerpe et al.,
2010). These previous studies demonstrated that the blood:saliva
ratios were not impacted by a range of factors including: CPF or
TCPy dose, pilocarpine dose, or the timing of saliva collection
(Smith et al., 2010, 2012). In Figures 3A–C where the time-
course of CPF (blood) and it major metabolite TCPy (blood
and saliva) are illustrated following a 5 mg/kg IV dose. These
results are very consistent with previous observations that CPF
undergoes rapid metabolism to TCPy (Poet et al., 2003; Timchalk
et al., 2007a; Busby-Hjerpe et al., 2010), although CPF was
detectable in three saliva samples (data not shown). Results
(Figure 3D) were also consistent with previous TCPy dosing
experiments where the ratio of TCPy in saliva/blood (ratios
∼0.04–0.06) demonstrated AUC linearity consistent with parallel
pharmacokinetics of TCPy in blood and saliva. These initial
in vivo studies in rats clearly demonstrate that saliva analyte
concentrations are highly proportional to blood concentrations
and PBPK model simulations accurately predict saliva/blood
concentrations over a range of doses, consistent with a diﬀusion
based transport mechanism.
Although in the rat in vivo model system saliva/blood TCPy
concentration ratios did not change over varying experimental
conditions (Figure 3D), as previously mentioned normal
diﬀerences in saliva pH values for humans (range 5.6–7.9)
have been noted in the literature (Hold et al., 1995b). Hence,
to adequately accommodate diﬀerences in partitioning due to
variable pH, and to enable accurate rat to human extrapolation
it was critical to simulate changes in analyte ionization states
FIGURE 3 | Groups of rats were administered a single intravenous (IV) dose of 5 mg/kg chlorpyrifos (CPF). (A) Concentration (μM) of CPF in blood; (B,C)
trichloropyridinol (TCPy) in blood and saliva, respectively; and (D) saliva:blood TCPy concentration ratios from 10–120 min post-dosing. Lines are PBPK model fit to
data.
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particularly when the pKa was bracketed by the pH range
of saliva. In this regard, the Schmitt algorithm provided a
good model prediction of the saliva/blood partitioning (Smith
et al., 2010). These initial ﬁnding do suggest that inter- and
intra-species diﬀerences in blood:saliva partitioning may be of
importance. To further evaluate the potential impact of these
diﬀerences a model sensitivity analysis was conducted.
Sensitivity Analysis
Model simulations and a sensitivity analysis was conducted to
further evaluate the impact of variable pKa (4−→10) or protein-
binding fractions (0.1−→0.9) on the saliva:blood partitioning
coeﬃcient. A summary of model parameters for both rat and
human are presented in Table 2. For the model sensitivity
analysis, it was assumed that generic compounds were 50%
bound to plasma proteins, the log Kow was 2 for non-ionized
compounds, and the log Kow was −1 for ionized compounds.
The sensitivity analysis (Table 3) speciﬁcally focused on four
TABLE 2 | Input chemical and tissue parameters used to simulate the
saliva:blood partitioning for generic over a range of pKa and
protein-binding values.
Parameter Value Source
Fraction unbound in plasma 0.1, 0.5, or 0.9 Fixed
PKa 4,7, or 10 Fixed
Log Kow @ non-ionized 2 Fixed
Log Kow @ ionized −1 Calculated from α
α 0.001 Schmitt (2008)
Tissue parameter Value (rat/human) Source
Plasma
Fraction protein 0.073 Ritschel and Tompson
(1983), Hold et al. (1995b)
Fraction water 0.915 Ritschel and Tompson
(1983), Hold et al. (1995b)
pH 7.4 Smith et al. (2010)
Saliva
Fraction cells 0 Estimated
Fraction protein 0.003 Ritschel and Tompson
(1983), Hold et al. (1995b)
Fraction water 0.98 Ritschel and Tompson
(1983), Hold et al. (1995b)
pH 8.9/6.7 Ritschel and Tompson
(1983), Hold et al. (1995b),
and Smith et al. (2010)
TABLE 3 | Sensitivity analysis for selected parameters for generalized
compound plasma:saliva partitioning coefficent.
Sensitivity coefficient (SC)
Species Fraction unbound in
plasma
Kow non-ionized Kow ionized pKa
Human 2.0 1.9 × 10−4 −1.6 × 10−2 0.9
Rat 2.0 2.2 × 10−4 3.9 × 10−3 −0.6
Absolute values for SC >0.5 suggest that model is highly sensitive to this
parameter. Model simulations were run at 50% protein-binding and pKa = 7.0,
Kow values from Table 2.
model parameters that modulate the plasma:saliva partitioning
coeﬃcient, these included: plasma protein-binding, Kow (non-
ionized and ionized) and pKa. For this analysis, the model is
highly sensitive [normalized sensitivity coeﬃcient (SC) >0.5] to
changes in plasma protein-binding (SC- 2.0) and pKa (−0.6 and
0.9) for both humans and rats. Hence, these parameters are of
critical importance and can substantially impact partitioning.
To illustrate the impact of plasma protein-binding on the
saliva:plasma partitioning coeﬃcient, model simulations were
conducted for three generic compounds with 0.1, 0.5, and 0.9
unbound fraction in plasma of rats and humans. It was assumed
that generic compounds had a pKa of 7, the log Kow was 2
for non-ionized compounds, the log Kow was −1 for ionized
compounds, and salivary pH was 6.7 and 8.9 for humans and
rats, respectively (Table 2). Model simulations are presented in
Figure 4. For both rats and humans the plasma:saliva partitioning
coeﬃcient increases as a function of the unbound chemical
fraction in plasma; however, it is also of interest to note that the
partitioning is substantially greater in humans (2.7–3.3x) than in
rats.
To further explore the impact of pH on the salivary:plasma
partition coeﬃcients a similar simulation was run but in this
case the protein-binding was assumed to be 50% while the pKa
values were 4, 7, and 10. As illustrated in Figure 5, generic
model simulations indicate that for those chemicals with pKa
of ∼7 the partitioning coeﬃcient will vary by a factor of 3
between rats and humans with substantially greater partitioning
in humans. However, for chemicals with low or high pKa values
(relative to pH) the rat and human plasma:saliva partitioning
are comparable. It is also important to note that inter-individual
diﬀerences is the extent of plasma protein-binding and saliva pH
within a population would also contribute to variations in the
saliva:plasma partitioning (data not shown); which could result
in variable salivary clearance.
FIGURE 4 | Physiologically based pharmacokinetic model simulation
of plasma:saliva partitioning coefficients for three generic compounds
with varying plasma protein-binding.
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FIGURE 5 | Physiologically based pharmacokinetic model simulation
of plasma:saliva partitioning coefficients for three generic compounds
with varying pKa values. Protein binding set at 50%.
Discussion
Physiologically based pharmacokinetic models have been
developed that incorporated saliva clearance as a computational
tool to quantify non-invasive biomonitoring of heavy metals
and pesticides (Timchalk et al., 2001, 2007b; Barry et al., 2009;
Smith et al., 2010, 2012). As previously noted, transcellular
diﬀusion (Figure 1) is thought to be the primary method by
which many drugs, chemicals, and pesticides, including the
CPF metabolite TCPy transfer from blood to saliva (Haeckel,
1993; Jusko and Milsap, 1993; Lu et al., 1997, 1998, 2003;
Smith et al., 2010, 2012). As noted in Figure 3D, in vivo
partitioning of TCPy from blood to saliva in rats is very
constant over a range of varying conditions which is entirely
consistent with a partitioning mechanism associated with
transcellular diﬀusion as proposed by Smith et al. (2010,
2012).
When considering transcellular or paracellular diﬀusion,
it is of interest to note that a number of physiochemical
properties including molecular size, lipid solubility, the
dissociation constant of ionized compounds, and the extent
of plasma-protein binding all contribute to modifying the
diﬀusion across a concentration gradient from blood to
saliva. In the current model simulation (Figure 3) the
analyte concentration in saliva (based upon partitioning) is
directly reﬂective of the concentration that is not bound to
plasma proteins in blood, since protein-analyte complexes
are too large for transcellular/paracellular diﬀusion (Haeckel,
1993; Jusko and Milsap, 1993; Lu et al., 1998; Smith et al.,
2012).
Likewise, as shown in Figure 5, the pH of blood and saliva
are important parameters modulating salivary clearance of
compounds particularly where the chemical pKa is comparable
to the pH of biological ﬂuids (Haeckel, 1993; Jusko and
Milsap, 1993). Although blood pH is reasonably consistent
(pH 7.4), saliva pH can vary and is primarily controlled
by the amount of bicarbonate present in saliva (Haeckel,
1993). Hence, due to variation in rat and human pH values
(Smith et al., 2010), the Schmitt algorithm (Schmitt, 2008)
has been utilized successfully to calculate plasma:saliva
partitioning. This modiﬁcation enables the extrapolation
of the blood to saliva analyte partitioning coeﬃcient to
humans over a range of reported human salivary pH
levels.
Although transcellular or paracellular diﬀusion across tight
junctions has been noted as a key transport mechanism for
many drugs and environmental contaminants (Haeckel, 1993;
Jusko and Milsap, 1993), both active and carrier-assisted cellular
transport may be of importance for some xenobiotics. In
this regard, transport is dependent upon speciﬁc rate-limiting
transport mechanisms. In salivary glands, unidirectional and
FIGURE 6 | Schematic model illustrating (A,B) Transwell R© with salivary
gland epithelial cell (SGEC) system. The tight junction marker zona
occludins-1 (ZO-1) localizes to points of cell–cell contact in association with
excellent tight junction formation as indicated by measurements of transepithelial
electrical resistance (TEER). (C) Western blot analysis showing expression of
α-amylase and AQ5 proteins in SGEC lysates indicative of acinar cells; and (D)
four-compartment (blood: RBC/plasma and salivary gland: interstitial and
cellular space) model structure for calculating steady-state transport.
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saturable inﬂux of amino acids, neurotransmitters, and drugs
have been shown to follow classic Michaelis–Menten kinetics
where aﬃnity and velocity constants can be experimentally
derived and computationally solved (Eq. 8). In this scenario, Tr
is the transport rate, Tmax the maximum rate of transport, Cu the
unbound analyte concentration and Km is the transport aﬃnity
constant. Hence, the current model structure can be readily
modiﬁed to accommodate these active transport processes;
thereby, enabling the models to simulate salivary clearance for a
broad range of chemicals and drugs.
Tr = TmaxCuKm + Cu (8)
For saliva biomonitoring to be more broadly utilized there is
a need to rapidly identify a comprehensive range of chemical
and drugs that can readily be quantiﬁed in saliva and utilized
to predict systemic dose based upon these saliva measurements.
A major limitation of the current experimental and modeling
strategy is the dependence upon in vivo animal model
systems as a means of identifying and screening chemical/drug
candidates for salivary clearance. In this regard, the current
in vivo models are limited by relatively low throughput and
experimental complexity. To address these limitations we are
developing an in vitro salivary gland epithelial cell based
Transwell R© assay to enable broad based screening of uptake
and clearance mechanisms associated with both diﬀusional and
active transport mechanisms (Figure 6; Weber et al., 2015).
Initial characterization of the cell system has demonstrated that
tight junctions are well formed and cells maintain functional
characteristics (Figure 6C) associated with salivary acinar
cells. The computational approach is based on a simpliﬁed
four-compartment model (Figure 6D) exploiting the Schmitt
algorithm (Schmitt, 2008) to describe diﬀusional based processes
along with active transport (Eq. 8). It is anticipated that this
novel experimental and computational strategy will enable the
prediction of chemical uptake and clearance in saliva for a broad
range of chemicals based upon limited in vitro experiments
which are integrated into the pharmacokinetic modeling
framework.
Conclusion
Biomonitoring is a critical tool for quantitatively evaluating
exposure from both environmental and occupational settings and
saliva has been advocated as a potentially important non-invasive
method that could be substituted for blood or urine. However,
there are a number of limitations that have hampered saliva’s use
in biomonitoring, including the need to initially identify which
chemicals are readily cleared in saliva at concentrations that can
be quantiﬁed. This review describes recent advances in the use
of a computational modeling approach that is closely coupled to
in vivo and in vitro experiments to predict salivary uptake and
clearance of xenobiotics. The approach simulates transcellular or
paracellular diﬀusion of unbound chemicals in plasma to saliva
using a combination of compartmental and physiologically based
computational models. Of key importance for determining the
plasma:saliva partitioning is the utilization of a modiﬁed Schmitt
algorithm (Schmitt, 2008) that calculates partitioning based
upon the tissue composition, pH, chemical pKa, and plasma
protein-binding. Sensitivity analysis of key model parameters
speciﬁcally identiﬁed that both protein-binding and pH/pKa had
the most signiﬁcant impact on the determination of partitioning
and that there were clear species dependent diﬀerences based
upon physiological variance between rats and humans. Future
research needs to focus on extending this modeling strategy
to an in vitro salivary acinar cell based system that can be
utilized to experimentally determine and computationally predict
salivary gland update and clearance for a broad range of
xenobiotics. Hence, it is envisioned that a combination of salivary
biomonitoring and computational modeling will enable the non-
invasive measurement of both environmental and occupational
exposure in human populations.
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